CROs/Service Providers

PharMerica introduces $25M share purchase program

Tuesday, July 3, 2012 09:22 AM

The board of directors of PharMerica, a national provider of institutional pharmacy and hospital pharmacy management services, has authorized an increase in its existing share purchase program that will allow the company to purchase up to $25 million of its common stock in the open market through unsolicited or solicited privately negotiated transactions, or in such other appropriate manner, and will be funded from available cash.

More... »

Pernix Therapeutics to acquire Great Southern Laboratories

Tuesday, July 3, 2012 09:08 AM

Pernix Therapeutics Holdings, a specialty pharmaceutical company of The Woodlands, Texas, has entered into a definitive agreement to acquire Great Southern Laboratories, a privately-held pharmaceutical contract manufacturing company of Houston, Texas.

More... »

Theradiag acquires Prestizia and microRNA technology platform

Monday, July 2, 2012 11:31 AM

Theradiag, a French theranostics and in vitro diagnostics company focused on autoimmune disease, has decided to acquire Prestizia, a French biotechnology company that develops microRNA technology.

More... »

ScinoPharm invests $37M in high potency cytotoxic injectable plant

Friday, June 29, 2012 02:50 PM

ScinoPharm, a Taiwanese provider of oncological APIs for injectable products, has decided to invest $37.6 million in the construction of a high potency cytotoxic injectable plant suitable for production of oncological injectable products on the company's premise at the Tainan Science Park.

More... »

Fluxion Biosciences, Stanford collaborate on circulating tumor cell analysis

Friday, June 29, 2012 11:45 AM

Fluxion Biosciences, a San Francisco-based provider of cellular analysis tools for use in critical life science, has formed a collaboration with the Stanford University School of Medicine to develop tests to help deliver more effective therapies to cancer patients.

More... »

Quotient Clinical, Capsugel collaborate on lipid-based formulations

Friday, June 29, 2012 11:23 AM

Quotient Clinical, a U.K. provider of specialist early stage drug development services, and Capsugel, a Morristown, N.J.-based provider of dosage solutions for the healthcare industry, have formed a collaboration to enable the rapid development and clinical assessment of lipid-based formulations. Together, the companies will use their technology and expertise to address the drug delivery challenges of poorly soluble molecules with limited oral bioavailability.

More... »

NERI nabs $18M NIH contract for pediatric circulatory support devices

Thursday, June 28, 2012 02:37 PM

New England Research Institutes (NERI), a privately held CRO that provides global, customized clinical trial solutions and registry services, has received an $18 million contract from the National Institutes of Health (NIH) for the PumpKIN Program for the development and clinical realization of novel pediatric circulatory support devices, such as ventricular assist devices (VADs) and extracorporeal membrane oxygenation devices (ECMOs).

More... »

LSK Global becomes first Korean partner to achieve Medidata Solutions accreditation

Thursday, June 28, 2012 12:54 PM

CRO LSK Global has strengthened its partnership with Medidata Solutions by becoming the first Korean partner to attain accreditation in the Medidata Partner Program.

More... »

PharmaNet/i3 introduces PharmaNet/i3 Strategic Resourcing

Thursday, June 28, 2012 11:46 AM

PharmaNet/i3, inVentiv Health’s clinical segment and provider of clinical development services, has launched PharmaNet/i3 Strategic Resourcing, a new unified provider of staffing and functional service provider (FSP) services.

More... »

RainDance and MLL collaborate on sequence-based analysis of myeloid malignancies

Monday, June 25, 2012 10:56 AM

MLL Munich Leukemia Laboratory (MLL) has purchased RainDance Technologies’ ThunderStorm System and consumables to process an initial 2,000 samples for use in the identification of prognostically relevant molecular mutations associated with acute myeloid leukemia (AML) and other myeloid malignancies.

More... »